Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558746 | 0.90 | KDM4E (0.45) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7233460 | 0.83 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7410232 | 0.78 | NR1H4 (0.39) | NPC1RAB9ANR1H4SMN1; SMN2KDM4E | |
| SCHEMBL28396885 | 0.77 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7235014 | 0.77 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14889093 | 0.77 | RAB9A (0.46) | NPC1RAB9ANR1H4SMN1; SMN2KDM4E | |
| SCHEMBL7241456 | 0.74 | GABRA1 (0.49) | KDM4ELMNAMAPTHSD17B10 | |
| SCHEMBL14889096 | 0.72 | GAA (0.56) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28391511 | 0.69 | GABRA2 (0.48) | MAPT | |
| SCHEMBL7554629 | 0.69 | KCNK3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | GABBR2, GABRP, GABBR1 | NPC1 941/4885RAB9A 2092/4885NR1H4 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.